<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:37:14Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10512105" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10512105</identifier>
        <datestamp>2023-09-22</datestamp>
        <setSpec>jamasd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id>
              <journal-title-group>
                <journal-title>JAMA Network Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2574-3805</issn>
              <publisher>
                <publisher-name>American Medical Association</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10512105</article-id>
              <article-id pub-id-type="pmcid">PMC10512105</article-id>
              <article-id pub-id-type="pmc-uid">10512105</article-id>
              <article-id pub-id-type="pmid">37728930</article-id>
              <article-id pub-id-type="pmid">37728930</article-id>
              <article-id pub-id-type="doi">10.1001/jamanetworkopen.2023.34695</article-id>
              <article-id pub-id-type="publisher-id">zld230180</article-id>
              <article-categories>
                <subj-group subj-group-type="category" specific-use="electronic">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Research Letter</subject>
                </subj-group>
                <subj-group subj-group-type="online-only">
                  <subject>Online Only</subject>
                </subj-group>
                <subj-group subj-group-type="subject-area">
                  <subject>Substance Use and Addiction</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Early Treatment Response in Black Smokers Undergoing Pharmacotherapy for Smoking Cessation</article-title>
                <subtitle>A Secondary Analysis of a Randomized Clinical Trial</subtitle>
                <alt-title alt-title-type="headline">Early Treatment Response Among Black Smokers Undergoing Pharmacotherapy</alt-title>
                <alt-title alt-title-type="running-head">Early Treatment Response Among Black Smokers Undergoing Pharmacotherapy</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Leavens</surname>
                    <given-names>Eleanor L. S.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zld230180aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mayo</surname>
                    <given-names>Matthew S.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zld230180aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Brown</surname>
                    <given-names>Alexandra R.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zld230180aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cox</surname>
                    <given-names>Lisa Sanderson</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zld230180aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ellerbeck</surname>
                    <given-names>Edward F.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MPH</degrees>
                  <xref rid="zld230180aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ahluwalia</surname>
                    <given-names>Jasjit S.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MPH</degrees>
                  <xref rid="zld230180aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nollen</surname>
                    <given-names>Nicole L.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zld230180aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="zld230180aff1"><label>1</label>Department of Population Health, University of Kansas School of Medicine, Kansas City</aff>
              <aff id="zld230180aff2"><label>2</label>Department of Biostatistics and Data Science, University of Kansas School of Medicine, Kansas City</aff>
              <aff id="zld230180aff3"><label>3</label>Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, Rhode Island</aff>
              <author-notes>
                <title>Article Information</title>
                <p><bold>Accepted for Publication:</bold> August 14, 2023.</p>
                <p content-type="published-online"><bold>Published:</bold> September 20, 2023. <?xpp bx;1?>doi:<uri content-type="doi">10.1001/jamanetworkopen.2023.34695</uri></p>
                <p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. © 2023 Leavens ELS et al. <italic>JAMA Network Open</italic>.</p>
                <corresp id="zld230180cor1"><bold>Corresponding Author:</bold> Eleanor L. S. Leavens, PhD, Department of Population Health, University of Kansas School of Medicine, Kansas City, KS 66160 (<email xlink:href="eleavens@kumc.edu">eleavens@kumc.edu</email>).</corresp>
                <p content-type="author-contributions"><bold>Author Contributions:</bold> Drs Leavens and Nollen had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p>
                <p><italic>Concept and design:</italic> Leavens, Mayo, Cox, Ellerbeck, Ahluwalia, Nollen.</p>
                <p><italic>Acquisition, analysis, or interpretation of data:</italic> Leavens, Mayo, Brown, Cox, Ahluwalia, Nollen.</p>
                <p><italic>Drafting of the manuscript:</italic> Leavens, Mayo, Brown, Nollen.</p>
                <p><italic>Critical review of the manuscript for important intellectual content:</italic> All authors.</p>
                <p><italic>Statistical analysis:</italic> Mayo, Brown.</p>
                <p><italic>Obtained funding:</italic> Ahluwalia, Nollen.</p>
                <p><italic>Administrative, technical, or material support:</italic> Leavens, Ellerbeck.</p>
                <p><italic>Supervision:</italic> Cox, Nollen.</p>
                <p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Drs Leavens, Mayo, Cox, Ellerbeck, Ahluwalia, and Nollen reported receiving grants from the National Institutes of Health outside the submitted work and during the conduct of the study. Dr Ahluwalia reported receiving consulting fees from and owning equity in Qnovia. No other disclosures were reported.</p>
                <p content-type="funding-statement"><bold>Funding/Support:</bold> This work was supported by grant R01 DA046576 from the NIH National Institute on Drug Abuse to Dr Nollen. Dr Ahluwalia was funded in part by Center of Biomedical Research Excellence grant P20GM130414 from the NIH. Pfizer Global Pharmaceuticals provided varenicline.</p>
                <p><bold>Role of the Funder/Sponsor:</bold> The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p>
                <p><bold>Disclaimer:</bold> The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p>
                <p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZLD230180-1-s" ref-type="supplementary-material">Supplement 3</xref>.</p>
              </author-notes>
              <pub-date pub-type="epub" iso-8601-date="2023-09-20T10:00">
                <day>20</day>
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>20</day>
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>6</volume>
              <issue>9</issue>
              <elocation-id>e2334695</elocation-id>
              <history>
                <date date-type="received">
                  <day>9</day>
                  <month>5</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>14</day>
                  <month>8</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright 2023 Leavens ELS et al. <italic>JAMA Network Open</italic>.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf-version" xlink:href="jamanetwopen-e2334695.pdf">jamanetwopen-e2334695.pdf</self-uri>
              <self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2023.34695"/>
              <abstract abstract-type="teaser" specific-use="electronic">
                <p>This secondary analysis of a randomized clinical trial investigates the association of early treatment response with smoking cessation among Black smokers.</p>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec id="H1-1-ZLD230180">
              <title>Introduction</title>
              <p>When smokers achieve abstinence in the first few weeks of treatment (ie, early treatment response), they have significantly greater odds of remaining abstinent at later times.<sup><xref rid="zld230180r1" ref-type="bibr">1</xref></sup> Understanding factors that increase odds of early response may help identify which individuals are likely to have early success and could guide clinical decision-making. This analysis examined early treatment response (abstinence at 2 weeks) and its effect on long-term abstinence (at 26 weeks) and identified baseline factors that increased odds of early response.</p>
            </sec>
            <sec id="H1-2-ZLD230180">
              <title>Methods</title>
              <p>The parent study to this secondary analysis (not prespecified) was an open-label randomized clinical trial among smokers who self-identified as non-Hispanic Black and were interested in quitting smoking.<sup><xref rid="zld230180r2" ref-type="bibr">2</xref>,<xref rid="zld230180r3" ref-type="bibr">3</xref></sup> After written informed consent, participants were randomized to standard (7 sessions of counseling with nicotine patch) or adaptive (including ≥2 pharmacotherapy adaptations [varenicline and bupropion with patch]) treatment. Groups received identical treatment with a 21-mg nicotine patch for the first 2 weeks. Adaptations occurred at weeks 2 and 6 based on biochemically confirmed smoking status, with carbon monoxide (CO) levels of 5 ppm or less indicating treatment response. Participants received 18 weeks of pharmacotherapy with long-term follow-up at week 26 (biochemically confirmed abstinence with anatabine and anabasine ≤2 ng/mL). The study was approved by the University of Kansas Medical Center’s Institutional Review Board and followed the <ext-link xlink:href="http://www.equator-network.org/reporting-guidelines/consort/" ext-link-type="uri">CONSORT</ext-link> reporting guideline (see trial protocol in <xref rid="note-ZLD230180-1-s" ref-type="supplementary-material">Supplement 1</xref> and study flowchart in the eFigure in <xref rid="note-ZLD230180-1-s" ref-type="supplementary-material">Supplement 2</xref>). This study did not require additional review, approval, or consent given that data were deidentified.</p>
              <p><xref rid="zld230180t1" ref-type="table">Table 1</xref> presents baseline biopsychosocial variables selected for this analysis based on studies of factors that increased odds of cessation. The effect of early treatment response (week 2) on long-term abstinence (week 26) was assessed using logistic regression with treatment included as a factor in the model; multiple logistic regression using best subset variable selection was used to investigate factors that increased odds of early treatment response. For the best subset analysis, 2 modeling strategies were used. The first forced treatment into the model; the second allowed but did not force treatment into the model. Results were unchanged. The second modeling strategy was selected because all participants were on identical treatment through week 2. Analyses were conducted for week 2 and 26 completers only using SAS statistical software version 9.4 (SAS Institute). All tests were 2-sided, and statistical significance was set at .05.</p>
              <table-wrap position="float" id="zld230180t1">
                <label>Table 1. </label>
                <caption>
                  <title>Baseline Factors and Their Association With Early Treatment Response<xref rid="zld230180t1n1" ref-type="table-fn"><sup>a</sup></xref></title>
                </caption>
                <table frame="hsides" rules="groups">
                  <col width="39.65%" span="1"/>
                  <col width="22.59%" span="1"/>
                  <col width="26.25%" span="1"/>
                  <col width="11.51%" span="1"/>
                  <thead>
                    <tr>
                      <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Baseline factor</th>
                      <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Participants, mean (SD) (N = 374)</th>
                      <th rowspan="2" valign="top" align="left" scope="col" colspan="1"><italic>P</italic> value<xref rid="zld230180t1n2" ref-type="table-fn"><sup>b</sup></xref></th>
                    </tr>
                    <tr>
                      <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Responders (n = 129)</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Nonresponders (n = 245)</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Demographic</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Age, y</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">54.9 (11.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">51.9 (11.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.01</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Socioeconomic</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Home ownership, No. (%)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">27 (20.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">37 (15.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.15</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Household annual income, $</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">25 971.7 (22 704.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">24 695.5 (19 268.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.59</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Smoking characteristic</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> CPD<xref rid="zld230180t1n3" ref-type="table-fn"><sup>c</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">10.4 (5.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">14.0 (7.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Menthol, No. (%)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1">.95</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Yes</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">114 (88.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">216 (88.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">15 (11.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">29 (11.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cigarette craving<xref rid="zld230180t1n4" ref-type="table-fn"><sup>d</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">32.1 (18.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">34.1 (18.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.33</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Nicotine withdrawal<xref rid="zld230180t1n5" ref-type="table-fn"><sup>e</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">7.7 (6.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">8.2 (6.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.52</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Psychosocial</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Neighborhood problems<xref rid="zld230180t1n6" ref-type="table-fn"><sup>f</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">14.9 (4.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">15.0 (4.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.86</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Neighborhood vigilance<xref rid="zld230180t1n7" ref-type="table-fn"><sup>g</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">16.1 (5.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">15.6 (5.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.39</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Marijuana use, No. (%)<xref rid="zld230180t1n8" ref-type="table-fn"><sup>h</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">26 (20.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">59 (24.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.39</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other tobacco product use, No. (%)<xref rid="zld230180t1n9" ref-type="table-fn"><sup>i</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3 (2.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">24 (9.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Perceived stress<xref rid="zld230180t1n10" ref-type="table-fn"><sup>j</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4.5 (3.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4.3 (3.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.61</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Experience of discrimination<xref rid="zld230180t1n11" ref-type="table-fn"><sup>k</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">5.9 (5.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">5.7 (5.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.81</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Resilience<xref rid="zld230180t1n12" ref-type="table-fn"><sup>l</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4.0 (0.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4.0 (0.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.61</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Anxiety<xref rid="zld230180t1n13" ref-type="table-fn"><sup>m</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4.3 (4.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4.7 (5.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.43</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Depression<xref rid="zld230180t1n14" ref-type="table-fn"><sup>n</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">5.2 (5.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">5.0 (5.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.96</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Biological</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cotinine level, ng/mL/1000</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2.5 (1.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3.6 (2.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Nicotine metabolite ratio, ng/mL</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2.9 (2.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3.8 (5.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.02</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <p>Abbreviations: CPD, cigarettes smoked per day; NA, not applicable.</p>
                  <fn id="zld230180t1n1">
                    <label>
                      <sup>a</sup>
                    </label>
                    <p>Biochemically confirmed by carbon monoxide (CO) levels of 5 ppm or less at week 2.</p>
                  </fn>
                  <fn id="zld230180t1n2">
                    <label>
                      <sup>b</sup>
                    </label>
                    <p><italic>T</italic> tests were performed for continuous measures, and χ<sup>2</sup> tests were performed for categorical or dichotomous measures.</p>
                  </fn>
                  <fn id="zld230180t1n3">
                    <label>
                      <sup>c</sup>
                    </label>
                    <p>Participants self-reported number of CPD during the past 7 days.</p>
                  </fn>
                  <fn id="zld230180t1n4">
                    <label>
                      <sup>d</sup>
                    </label>
                    <p>Questionnaire of Smoking Urges-Brief (range, 10-70; higher scores indicate greater smoking urge).</p>
                  </fn>
                  <fn id="zld230180t1n5">
                    <label>
                      <sup>e</sup>
                    </label>
                    <p>Minnesota Tobacco Withdrawal Scale (range, 0-32; higher scores indicate greater symptoms of withdrawal).</p>
                  </fn>
                  <fn id="zld230180t1n6">
                    <label>
                      <sup>f</sup>
                    </label>
                    <p>A 10-item scale described problems that could arise in any area. Participants rated the extent of each problem using a 3-point scale from 1 (not a problem) to 2 (some problem) to 3 (serious problem). Answers were summed for the total score (range, 10-30).</p>
                  </fn>
                  <fn id="zld230180t1n7">
                    <label>
                      <sup>g</sup>
                    </label>
                    <p>Vigilance for Threat scale (range, 6-30; higher scores indicate greater perceived threat).</p>
                  </fn>
                  <fn id="zld230180t1n8">
                    <label>
                      <sup>h</sup>
                    </label>
                    <p>Participants self-reported marijuana use in the past 7 days (yes or no).</p>
                  </fn>
                  <fn id="zld230180t1n9">
                    <label>
                      <sup>i</sup>
                    </label>
                    <p>Self-reported past 7-day use of other tobacco products, including cigars, cigarillos, pipes, smokeless tobacco, hookah, or bidis (yes or no).</p>
                  </fn>
                  <fn id="zld230180t1n10">
                    <label>
                      <sup>j</sup>
                    </label>
                    <p>Perceived Stress Scale (range, 0-16; higher scores indicate greater perceived stress).</p>
                  </fn>
                  <fn id="zld230180t1n11">
                    <label>
                      <sup>k</sup>
                    </label>
                    <p>Frequency of perceived discrimination in day-to-day experience, with response options ranging from 0 (“never”) to 5 (“almost every day”); overall range was 0 to 25.</p>
                  </fn>
                  <fn id="zld230180t1n12">
                    <label>
                      <sup>l</sup>
                    </label>
                    <p>Brief Resilience Scale (range, 1-5; higher scores indicate greater resilience).</p>
                  </fn>
                  <fn id="zld230180t1n13">
                    <label>
                      <sup>m</sup>
                    </label>
                    <p>Generalized Anxiety Disorder-7 (0-4 [minimal anxiety], 5-9 [mild anxiety], 10-14 [moderate anxiety], and ≥15 [severe anxiety]).</p>
                  </fn>
                  <fn id="zld230180t1n14">
                    <label>
                      <sup>n</sup>
                    </label>
                    <p>Patient Health Questionnaire-2 (scores ≥3 may indicate major depressive disorder).</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
            </sec>
            <sec id="H1-3-ZLD230180">
              <title>Results</title>
              <p>After accounting for treatment differences among 374 participants (mean [SD] age, 53.0 [11.4] years; 153 males [40.9%]), early treatment response increased odds of long-term abstinence (odds ratio, 3.6; 95 CI, 1.9-6.8; <italic>P</italic> &lt; .001). Results were unchanged when individuals with missing data were treated as nonresponders (week 2) and smokers (week 26). See <xref rid="zld230180t1" ref-type="table">Table 1</xref> for baseline factors for 129 early responders and 245 nonresponders. There were 3 factors that increased odds of early treatment response: fewer cigarettes per day, nonuse of other tobacco products, and lower cotinine levels (<xref rid="zld230180t2" ref-type="table">Table 2</xref>).</p>
              <table-wrap position="float" id="zld230180t2">
                <label>Table 2. </label>
                <caption>
                  <title>Best 1-4 Factors Associated With Early Response<xref rid="zld230180t2n1" ref-type="table-fn"><sup>a</sup></xref></title>
                </caption>
                <table frame="hsides" rules="groups">
                  <col width="26.59%" span="1"/>
                  <col width="18.21%" span="1"/>
                  <col width="18.21%" span="1"/>
                  <col width="18.76%" span="1"/>
                  <col width="18.23%" span="1"/>
                  <thead>
                    <tr>
                      <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Baseline factor</th>
                      <th colspan="4" valign="top" align="left" scope="colgroup" rowspan="1">Early response, OR (95% CI)</th>
                    </tr>
                    <tr>
                      <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Best 1 factor</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Best 2 factor</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Best 3 factor<xref rid="zld230180t2n2" ref-type="table-fn"><sup>b</sup></xref></th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Best 4 factor</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">CPD<xref rid="zld230180t2n3" ref-type="table-fn"><sup>c</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.91 (0.88-0.95)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.91 (0.88-0.95)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.93 (0.89-0.96)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.93 (0.90-0.97)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Other tobacco use</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.19 (0.06-0.65)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.18 (0.05-0.63)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.20 (0.06-0.70)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cotinine level<xref rid="zld230180t2n4" ref-type="table-fn"><sup>d</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.86 (0.78-0.96)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.85 (0.76-0.94)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Nicotine metabolite ratio<xref rid="zld230180t2n5" ref-type="table-fn"><sup>e</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.93 (0.67-1.01)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Home ownership</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Best model fit statistics</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">χ<sup>2</sup>, 22.0; AIC intercept covariates, 461.5; −2 log <italic>L</italic> intercept covariates, 457.5; proportion concordant, 63.1%; proportion discordant, 32.4%; <italic>Somers D</italic>, 0.31; γ, 0.32; τ-<italic>a</italic>, 0.14; <italic>C</italic> statistic, 0.65.</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">χ<sup>2</sup>, 29.8; AIC intercept covariates, 453.7; −2 log <italic>L</italic> intercept covariates, 447.7; proportion concordant, 65.6%; proportion discordant, 30.1%; Somers <italic>D</italic>, 0.36; γ, 0.37; τ-<italic>a</italic>, 0.16; <italic>C</italic> statistic, 0.68.</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">χ<sup>2</sup>, 37.1; AIC intercept covariates, 447.4; −2 log <italic>L</italic> intercept covariates, 439.4; proportion concordant, 69.4%; proportion discordant, 30.6%; Somers <italic>D</italic>, 0.39; γ, 0.39; τ-<italic>a</italic>, 0.18; <italic>C</italic> statistic, 0.69.</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">χ<sup>2</sup>, 40.6; AIC intercept covariates, 444.9; −2 log <italic>L</italic> intercept covariates, 434.9; proportion concordant, 70.0%; proportion discordant, 30.0%; Somers <italic>D</italic>, 0.40; γ, 0.40; τ-<italic>a</italic>, 0.18; <italic>C</italic> statistic, 0.70.</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <p>Abbreviations: AIC, Akaike information criterion; CPD, cigarettes per day; NA, not applicable; OR, odds ratio.</p>
                  <fn id="zld230180t2n1">
                    <label>
                      <sup>a</sup>
                    </label>
                    <p>Early abstinence was defined by week 2 verified carbon monoxide (CO) levels of 5 ppm or less.</p>
                  </fn>
                  <fn id="zld230180t2n2">
                    <label>
                      <sup>b</sup>
                    </label>
                    <p>The 3-factor model had the best fit statistics while maintaining parsimony and significance of factors in the model.</p>
                  </fn>
                  <fn id="zld230180t2n3">
                    <label>
                      <sup>c</sup>
                    </label>
                    <p>Per 1-cigarette increase.</p>
                  </fn>
                  <fn id="zld230180t2n4">
                    <label>
                      <sup>d</sup>
                    </label>
                    <p>Per 1000-unit increase in cotinine.</p>
                  </fn>
                  <fn id="zld230180t2n5">
                    <label>
                      <sup>e</sup>
                    </label>
                    <p>Nicotine metabolite ratio is continuous.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
            </sec>
            <sec id="H1-4-ZLD230180">
              <title>Discussion</title>
              <p>In this study, early treatment responders had 3.6-fold greater odds of achieving long-term abstinence compared with nonresponders. Early responders smoked fewer cigarettes per day, reported nonuse of other tobacco products, and had lower cotinine levels at baseline. These findings may inform clinical decision-making by identifying patients likely to respond successfully to a nicotine patch, a minimal, low-cost intervention, and those who may benefit from more intensive or alternative intervention. Our findings underscore the importance of follow-up within 2 to 4 weeks of the quit date. If patients have not quit within 2 to 4 weeks, transitioning to a different treatment may be beneficial. Interestingly, the parent study showed that additional adaptations to other pharmacotherapies did not rescue a significant number of smokers.<sup><xref rid="zld230180r3" ref-type="bibr">3</xref></sup> Consistent with the tipping point hypothesis, many smokers receive little benefit from even intensive interventions.<sup><xref rid="zld230180r4" ref-type="bibr">4</xref></sup> For smokers unable to quit, harm reduction strategies, including e-cigarettes, are recommended as part of a shared decision-making approach.<sup><xref rid="zld230180r5" ref-type="bibr">5</xref>,<xref rid="zld230180r6" ref-type="bibr">6</xref></sup></p>
              <p>This study was limited to Black individuals who were light to moderate smokers with low prevalence of other tobacco use recruited from a single Midwestern city who were motivated to quit smoking. While this assessment included numerous biopsychosocial factors that may impact treatment response, other factors may merit future research.</p>
            </sec>
          </body>
          <back>
            <ref-list id="REF-ZLD230180">
              <title>References</title>
              <ref id="zld230180r1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ferguson</surname><given-names>SG</given-names></string-name>, <string-name><surname>Gitchell</surname><given-names>JG</given-names></string-name>, <string-name><surname>Shiffman</surname><given-names>S</given-names></string-name>, <string-name><surname>Sembower</surname><given-names>MA</given-names></string-name></person-group>. <article-title>Prediction of abstinence at 10 weeks based on smoking status at 2 weeks during a quit attempt: secondary analysis of two parallel, 10-week, randomized, double-blind, placebo-controlled clinical trials of 21-mg nicotine patch in adult smokers</article-title>. <source>Clin Ther</source>. <year>2009</year>;<volume>31</volume>(<issue>9</issue>):<fpage>1957</fpage>-<lpage>1965</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.clinthera.2009.08.029</pub-id><?supplied-pmid 19843485?><pub-id pub-id-type="pmid">19843485</pub-id></mixed-citation>
              </ref>
              <ref id="zld230180r2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Nollen</surname><given-names>NL</given-names></string-name>, <string-name><surname>Cox</surname><given-names>LS</given-names></string-name>, <string-name><surname>Mayo</surname><given-names>MS</given-names></string-name>, <etal/></person-group>. <article-title>Protocol from a randomized clinical trial of multiple pharmacotherapy adaptations based on treatment response in African Americans who smoke</article-title>. <source>Contemp Clin Trials Commun</source>. <year>2022</year>;<volume>30</volume>:<elocation-id>101032</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.conctc.2022.101032</pub-id><?supplied-pmid 36387983?><pub-id pub-id-type="pmid">36387983</pub-id></mixed-citation>
              </ref>
              <ref id="zld230180r3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Nollen</surname><given-names>NL</given-names></string-name>, <string-name><surname>Ahluwalia</surname><given-names>JS</given-names></string-name>, <string-name><surname>Mayo</surname><given-names>MS</given-names></string-name>, <etal/></person-group>. <article-title>Multiple pharmacotherapy adaptations for smoking cessation based on treatment response in Black adults who smoke: a randomized clinical trial</article-title>. <source>JAMA Netw Open</source>. <year>2023</year>;<volume>6</volume>(<issue>6</issue>):<elocation-id>e2317895</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.17895</pub-id><?supplied-pmid 37338906?><pub-id pub-id-type="pmid">37338906</pub-id></mixed-citation>
              </ref>
              <ref id="zld230180r4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Baker</surname><given-names>TB</given-names></string-name>, <string-name><surname>Bolt</surname><given-names>DM</given-names></string-name>, <string-name><surname>Smith</surname><given-names>SS</given-names></string-name></person-group>. <article-title>Barriers to building more effective treatments: negative interactions amongst smoking intervention components</article-title>. <source>Clin Psychol Sci</source>. <year>2021</year>;<volume>9</volume>(<issue>6</issue>):<fpage>995</fpage>-<lpage>1020</lpage>. doi:<pub-id pub-id-type="doi">10.1177/2167702621994551</pub-id><?supplied-pmid 35003904?><pub-id pub-id-type="pmid">35003904</pub-id></mixed-citation>
              </ref>
              <ref id="zld230180r5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hartmann-Boyce</surname><given-names>J</given-names></string-name>, <string-name><surname>McRobbie</surname><given-names>H</given-names></string-name>, <string-name><surname>Butler</surname><given-names>AR</given-names></string-name>, <etal/></person-group> Electronic cigarettes for smoking cessation. <source>Cochrane Database Syst Rev</source>. <year>2021</year>;<volume>9</volume>(<issue>9</issue>):<elocation-id>CD010216</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/14651858.CD010216.pub6</pub-id><?supplied-pmid 34519354?><pub-id pub-id-type="pmid">34519354</pub-id></mixed-citation>
              </ref>
              <ref id="zld230180r6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Warner</surname><given-names>KE</given-names></string-name>, <string-name><surname>Benowitz</surname><given-names>NL</given-names></string-name>, <string-name><surname>McNeill</surname><given-names>A</given-names></string-name>, <string-name><surname>Rigotti</surname><given-names>NA</given-names></string-name></person-group>. <article-title>Nicotine e-cigarettes as a tool for smoking cessation</article-title>. <source>Nat Med</source>. <year>2023</year>;<volume>29</volume>(<issue>3</issue>):<fpage>520</fpage>-<lpage>524</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-022-02201-7</pub-id><?supplied-pmid 36788367?><pub-id pub-id-type="pmid">36788367</pub-id></mixed-citation>
              </ref>
            </ref-list>
            <notes notes-type="supplementary-material" id="note-ZLD230180-1">
              <supplementary-material id="note-ZLD230180-1-s" position="float" content-type="local-data">
                <label>Supplement 1.</label>
                <caption>
                  <p>
Trial Protocol
</p>
                </caption>
                <media xlink:href="jamanetwopen-e2334695-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 2.</label>
                <caption>
                  <p><bold>eFigure.</bold> Study Flowchart</p>
                </caption>
                <media xlink:href="jamanetwopen-e2334695-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 3.</label>
                <caption>
                  <p>
Data Sharing Statement
</p>
                </caption>
                <media xlink:href="jamanetwopen-e2334695-s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </notes>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
